 (Martin et 
Parathyroid hormone-related protein (PTHrP) was initially discovered as a tumour product involved in malignancyassociated hypercalcaemia and has since been identified in a wide range of tumours as well as in normal tissues Moseley and Gillespie, 1992) . The protein exhibits sufficient N-terminal homology with PTH to interact with the PTH receptor, accounting for its PTH-like actions in promoting hypercalcaemia (Abou-Samra et al., 1992) . The human PTHIPTHrP receptor has been cloned from kidney and osteoblast-like osteosarcoma cell cDNA libraries and was found to be a member of a family of seven transmembrane domain, G-protein-linked receptors (Schipani et al., 1993) . The remainder of the PTHrP sequence diverges from that of PTH and possesses non-PTH-like actions, including roles in placental calcium transport (Rodda et al., 1988) , inhibition of osteoclastic bone resorption in vitro (Fenton et al., 1991) and cell growth andbor differentiation (Henderson et al., 1991) .
The human PTHrP gene consists of nine exons. of which only two are present in all PTHrP transcripts: exon V, encoding the prepro region of the protein, and exon VI, which encodes the majority of the coding region for the mature protein up to residue 139, where a splice donor site is located. Readthrough of exon VI to exon VII introduces a stop codon and produces mRNA for the 139 amino acid isoform, while splicing of exon VI to exon VIII or IX results in mRNA specifying the 173 and 141 amino acid isoforms respectively (Suva et al., 1987; Mangin et al., 1988a Mangin et al., ,b, 1989 Thiede et al., 1988; Yasuda et al., 1989) . Thus, alternative 3' splicing allows the production of mRNA specifying three isofoms of PTHrP which differ in their C-terminal regions. Three promoters have been identified in the gene: two TATA promoters, 5' to exons I and IV (P1 and P3 respectively) (Thiede et al.. 1988; Mangin et al., 1989 Mangin et al., , 1990 Suva et al.. 1989 : Yasuda et al.. 1989 , and a GC-rich promoter, 5' to exon III (P2) (Vasavada et al.. 1993) . In addition, exon II may be included in or excluded from transcripts originating from promoter 1 (Mangin et al.. 1990; Glatz et al., 1994) , or exon I may be spliced directly to exon V (Glatz et al., 1994) . We and others have demonstrated in cell lines that more than one promoter may be utilised and alternative splicing events occur (Mangin et al.. 1990; Southby et al., 1993; Vasavada et al., 1993; Brandt et al., 1994; Glatz et al., 1994) . The presence of three promoters and 5' and 3' alternative splicing suggests that PTHrP expression may be differentially regulated by growth factors during development or in a tissue-specific manner. It has been suggested that tissuespecific splicing of PTHrP mRNA does occur (Mangin et al., 1989; Campos et al., 1992; Brandt et al., 1994) , however these studies utilised only cell lines (Brandt et al., 1994) or a small number of primary tumours (Mangin et al., 1989; Campos et al., 1992 PCR was initially performed using primers to the two invariant exons of PTHrP mRNA, exons V and VI ( Figure  1 ), in order to assess PTHrP mRNA production (Figure 2) . A band of the appropriate size (161 bp) was observed for each sample, which hybridised with an internal PTHrP oligonucleotide (obrf 15.8), confirming that the PCR products were the results of specific amplification of PTHrP mRNA. Thus all of the tumour and normal tissues examined expressed PTHrP mRNA (Figure 2) .
To address which of the PTHrP isoforms the tumours were capable of producing (i.e. 139. 141 or 173 amino acid isoforms), the 3' alternative splicing patterns were investigated by amplifying between the common exon V and the alternative exons VII. VIII and IX (Figure 1) . All of the breast tumours studied used each of the three 3' splicing pathways (Figure 2a . Bi -B 13) and thus expressed mRNA specifying each of the three PTHrP isoforms. A similar pattern of 3' splicing was observed with the renal samples ( Figure 2b ). Splicing of exon VI to each of the three alternative 3' exons occurred in both the normal renal tissue (NI and N2) and the tumour samples (RI -R6). Three of the normal lung samples (Figure 2c , NI -N3) and the 13 lung tumours (LI -L13) utilised the exon VII and exon IX splicing pathways. The fourth normal lung sample (N4) used the exon IX but not the exon VII splicing pathway. Exon VI was spliced to exon VIII in only three of the normal samples (NI.
N3, N4) and nine of the tumours (Figure 2c To differentiate between the use of the PTHrP promoters. PCR was carried out using primers to the alternative 5' exons, specific to transcripts derived from each of the promoters (P1, P2 and P3). and the common exon VI (Figure 1 III (Glatz et al., 1994) . Thus amplification between exons I. III and IV and exon VI allowed the usage of P1. P2 and P3 respectively. to be determined (Glatz et al., 1994) .
Promoter 1 transcripts were detected in seven of the 13 breast tumours, as determined by amplification between exons I and VI (Figure 2a) . Two products were identified in four of these tumours (B1. B4, B5 and B8) (Figure 2a , B7, B10 and B12) in which P1 was active appeared to use only the I-II-III-V-VI splicing pathway. One of the two normal renal samples (N1) and all of the six renal tumours (RI -R6) contained P1 transcripts (Figure 2b) , with the normal tissue and three of the tumours (R3-R5) utilising the I-II-III-V-VI splicing pathway only. Two renal tumours (RI and R6) appeared to produce P1 transcripts both with and without exon II and the remaining tumour (R2) produced only P1 transcripts in which exon II had been spliced out. P1 transcripts were present in one sample of normal lung tissue (NI) and in six of the lung tumours (Figure 2c ). P1 transcripts both with and without exon II were identified in the normal tissue (NI) and three of the lung tumours (L5, L6 and L9), while P1 only transcripts containing exon II were detected in the other three lung tumours (LI, L2 and LI 1). P1 transcripts containing exon II were identified in the oesophageal tumour (E), the hepatoma (H) and one of the parathyroid samples (PT1; Figure 2d) . The other parathyroid sample in which P1 was active (PT3) contained P1 transcripts both with and without exon II (Figure 2d) .
PCR was performed between exons III and VI to determine usage of the GC-rich promoter. Promoter 2-specific transcripts were detected in eight of the 13 breast tumours (Figure 2a ) and all of the renal samples except one tumour sample (Figure 2b, R4 ). P2-initiated transcripts were not detected in the normal lung tissues but were present in five of the lung tumours (L3. L5, L6. L9 and LI 1); four of the lung tumours (L5. L6. L9 and L11) contained both P1-and P2-initiated transcripts (Figure 2c ). The oesophageal tumour (E) and two of the five parathyroid samples (PT2, PT3) also contained P2 transcripts (Figure 2d ).
In contrast to the more restricted utilisation of P1 and P2, P3-initiated transcripts were detected in all of the tissue samples. While many of the samples utilised all three promoters, there were examples of use of P1 but not P2 and vice versa.
Overall, the use of P3 and splicing to exon IX appeared to be common to all normal and tumour tissues and all except PTHrP aIrnatve mRNA splicng J Southby et al two samples used the exon VII splicing pathway but there was differential use of the alternative exon VIII and of the two upstream promoters P1 and P2. Each group of tumours exhibited an array of splicing patterns and there did not appear to be a splicing preference particular to one tissue or tumour type.
For the two normal kidney samples and three of the four normal lung samples there was also tumour tissue from the same patient (renal: NI R2. N2 R3: lung: NI L9. N2 L2. N4 L6). The same splicing patterns were observed in the normal and tumorous renal tissues except for the use of P1 in one pair: P1 was not active in one normal renal sample (N2) but P1 transcripts were detected in the tumour counterpart (R3; Figure 2b) . In comparing the normal and tumour lung samples (Figure 2c) , two normal lung samples used P1 and P3 (Ni) or P3 only (N4) while their tumour counterparts utilised all three promoters (L9 and L6 respectively). Promoter 3 only was active in the third normal lung sample (N2) while P1 and P3 were active in the tumour (L2). One normal sample (N4) lacked exon VII-containing mRNA and another (N2) lacked exon VIII-containing mRNA while the corresponding tumours (L6 and L2) utilised all three 3' splicing pathways. This would result in the two lung tumour samples. L2 and L6, producing each of the three PTHrP protein isoforms, while their corresponding normal samples. N2 and N4, are predicted to only produce the 139 and 141 or the 173 and 141 amino acid isoforms respectively.
In addition, the tissue and tumour samples were examined for the presence of PTH/PTHrP receptor mRNA. Amplification with two receptor-specific primers detected mRNA for the PTH/PTHrP receptor in all of the samples (Figure 2 ).
RT-PCR with GAPDH primers was performed as a control for the quality of the extracted RNA and for the reverse transcription reaction. Each of the tissue and tumour samples displayed a band on PCR with the GAPDH primers which hybridised with the internal GAPDH oligonucleotide. GAPDH-1 (Figure 2 ).
Discussion
The human PTHrP gene has a complex organisation. with nine exons. three promoters and multiple splicing pathways Moseley and Gillespie, 1992) . Initial studies have raised the possibility of tissue-specific splicing of PTHrP transcripts (Mangin et al.. 1989; Brandt et al.. 1992 Brandt et al.. , 1994 Campos et al., 1992) . however these studies were limited by the number of samples analysed or failure to examine the use of all three promoters at a time when the complete exonic structure had not been resolved; the GC-rich promoter, P2, had not been identified. Mangin et al. (1989) assessed the PTHrP mRNA splicing pathways of four human tumours of different types and found that the tumours displayed different 3' splicing pathways, leading to the suggestion that the PTHrP mRNA splicing patterns were tumour-specific. Campos et al. (1992) (Mangin et al., 1988a (Mangin et al., , 1989 Ikeda et al., 1988; Danks et al.. 1989 Danks et al.. , 1990 Southby et al., 1990; Campos et al.. 1992) . Immunohistochemical staining for PTHrP in breast. renal and lung tumours was mostly confined to the tumour cells, with only occasional staining observed in the stroma or in blood vessels (Danks et al.. 1989 Southby et al.. 1990) In a number of cases. normal and tumour tissue were obtained from the same patient. In each case where the splicing patterns differed, there was an increase in the number of promoters used and. in two cases, there was also an increase in the number of 3' splicing pathways utilised in some lung tumour samples. compared with the normal tissue. This is perhaps a result of altered regulation as a consequence of transformation to the cancer state and suggests a general increase in PTHrP transcription in the tumour cells which possibly contributes to the overexpression of PTHrP in those tumours which cause hypercalcaemia.
Identification of PTH/'PTHrP receptor mRNA in the normal kidney and renal tumours was expected, given that the kidney is one of the targets of PTH action. Breast and lung are not classical sites of PTH action. however PTH tPTHrP receptor mRNA has been detected in many rat tissues, including breast and lung (Urena et al.. 1993) . Since PTHrP has been detected in vascular smooth muscle (de Papp and Stewart, 1993) and shown to induce vascular relaxation (Winquist et al., 1987) it is possible that the PTH 'PTHrP receptor mRNA detected is denrved from the blood vessels of the tissues. However if the PTH PTHrP receptor is present in the same tissues which produce PTHrP it suggests that if the PTHrP is secreted it may potentially act on the same cell or neighbounrng cells. possibly affecting the growth and differentiation of the tumour.
